In preclinical studies, IGF1R activation mediated the acquisition of resistance to dacomitinib and WZ4002 mainly through activation of PI3K-AKT pathway in EGFR-mutant NSCLC cells, while MAPK pathway was activated subsequently only when prolonged the drug exposure [76]. The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.